Protein / target
Synaptosomal-associated protein 25
Protein at a glance
Biological role
Voltage-gated potassium channel
Strongest disease association
Congenital myasthenic syndromes
Therapeutic position
Established drug target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
t-SNARE involved in the molecular regulation of neurotransmitter release.
View complete UniProt function annotationHide complete annotation
t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells
Subcellular location
Domains and Gene Ontology detail (39)Hide
Domains & features
Gene Ontology
- Ccell cortex
- Ccytoplasm
- Ccytoskeleton
- Ccytosol
- Cglutamatergic synapse
- Cgrowth cone
- Cmembrane
- Cneuron projection
- Cperinuclear region of cytoplasm
- Cphotoreceptor inner segment
- Cplasma membrane
- Cpresynaptic membrane
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·Synapse, synaptosome
- ·glutamatergic synapse
- ·presynaptic membrane
- ·ribbon synapse
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
6 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
Indicated for Migraine Disorders, Urinary Bladder, Overactive, Urinary Incontinence, Urge
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene SNAP25
Gene-level evidence surfaced through the gene SNAP25that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (4)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
8 compounds recorded · 6 approved · 2 in clinical development
View all recorded compounds (8)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (7)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial results posted
The Effect of Zinc Supplementation Prior to Botulinum Neurotoxin Type A Injection in the Treatment of Spasmodic Dysphonia
- Trial status changed
The Effect of Zinc Supplementation Prior to Botulinum Neurotoxin Type A Injection in the Treatment of Spasmodic Dysphonia
- Indication expanded
Indication expansion: INCOBOTULINUMTOXINA (BLA125360)
- Label change
Label change: INCOBOTULINUMTOXINA (BLA125360)
- Label change
Label change: INCOBOTULINUMTOXINA (BLA125360)
- Label change
Label change: INCOBOTULINUMTOXINA (BLA125360)
- Indication expanded
Indication expansion: INCOBOTULINUMTOXINA (BLA125360)
- Label change
Label change: INCOBOTULINUMTOXINA (BLA125360)
- New publicationEfficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas: A Randomized Clinical Trial.
- New publicationIntraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial.
- New publicationBotulinum toxin A for the treatment of delayed gastric emptying.
- New publicationImpact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.